SCHEMBL190469

SCHEMBL190469

NCc1cc(-c2ccc(OCc3ccccc3)cc2)no1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.66
RAB9A P51151 5/20 0.63
NPC1 O15118 4/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
L3MBTL1 Q9Y468 4/20 0.63
TDP1 Q9NUW8 3/20 0.63
MAPT P10636 3/20 0.62
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
POLB P06746 2/20 0.54
MAOB P27338 1/20 0.51
PTGS1 P23219 2/20 0.51
PTGS2 P35354 2/20 0.51
XDH P47989 1/20 0.50
SMPD1 P17405 1/20 0.50
ENPP3 O14638 1/20 0.49
ENPP1 P22413 1/20 0.49
MGAM O43451 1/20 0.49
GAA P10253 1/20 0.49
SI P14410 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3789944 0.87 HPGD (0.52) NOTUMRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL189559 0.86 NOTUM (0.66) NOTUMRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL190599 0.86 RAB9A (0.64) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1
SCHEMBL190007 0.85 RAB9A (0.55) NOTUMRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL190343 0.83 RAB9A (0.62) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1
SCHEMBL3990026 0.83 NOTUM (0.73) NOTUMRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL189840 0.83 RAB9A (0.59) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1
SCHEMBL189501 0.81 RAB9A (0.59) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1
SCHEMBL9382780 0.81 RAB9A (0.94) NOTUMRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL189495 0.81 SMN1; SMN2 (0.53) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP disclosed
US-8828992-B2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-09 US disclosed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP disclosed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US disclosed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME MAOB, MAOA, PARK7 NOTUM 1260/4885RAB9A 1245/4885NPC1 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.